Survey on the use of molecular targeted drugs for advanced hepatocellular carcinoma.

Survey on the use of molecular targeted drugs for unresectable hepatocellular carcinoma. - Molecularly targeted drugs investigation for unresectable hepatocellular carcinoma.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050223

Enrollment

100

Registered

2023-02-02

Start date

2018-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with a histological or clinical (imaging and tumour markers) diagnosis of hepatocellular carcinoma whose attending physician determines that the use of molecularly targeted drugs is appropriate in routine practice are eligible for the study.

Exclusion criteria

Exclusion criteria: Patients who indicated their intention not to participate in the study

Design outcomes

Primary

Measure	Time frame
After identifying patient selection and exclusion criteria, patients will be enrolled and observed until withdrawal of consent, patient death, last hospital visit (loss to follow-up) or end of study period (one year after last enrolled case). Safety will be investigated during this observation period.	—

Secondary

Measure	Time frame
Investigate patient background, treatment, efficacy and patient outcomes.	—

Countries

Japan

Contacts

Public ContactRie Sugimoto

National Hospital Organization Kyushu Cancer Center Department of Hepato-Biliary-Pancreatology

sugirie5@rr.iij4u.or.jp0925413231

Outcome results